Uric acid reducing polypeptide as well as preparation method and application thereof
The uric acid-lowering polypeptide prepared through Bacillus subtilis fermentation culture and pepsin enzymatic decomposition solves the treatment problem of hyperuricemia, achieves a significant uric acid-lowering effect, and has important clinical application value.
Patent Information
- Application Number
- CN202411408827.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-10
- Publication Date
- 2024-11-19
AI Technical Summary
The incidence of metabolic diseases caused by hyperuricemia, such as gout, renal failure, coronary heart disease and diabetes, is gradually increasing, and the existing technology has not yet effectively solved the research on uric acid reduction based on natto.
Nattokinase is prepared by fermenting and cultured Bacillus subtilis and enzymatically dissolved with pepsin to obtain a polypeptide of uric acid reduction. The process is simple and suitable for large-scale production, and has significant uric acid reduction effect.
The prepared uric acid-lowering polypeptide can inhibit xanthine oxidase activity, significantly reduce serum uric acid levels, has important R&D and clinical application value, and has no toxic side effects.
Smart Images

Figure CN118979091A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of bioengineering technology, and specifically to a uric acid-lowering polypeptide and a preparation method and application thereof. Background Art
[0002] Hyperuricemia (HUA) is a metabolic disease caused by excessive production of uric acid or obstructed excretion in the body, and its clinical manifestations are elevated serum uric acid levels. Uric acid is the final product of purine metabolism in the human body, and is mainly formed by a series of enzymatic reactions of nucleic acids and other purine substances decomposed by cell metabolism and food-borne purines. Patients with hyperuricemia are usually prone to gout. At the same time, hyperuricemia can also cause a variety of metabolic syndromes, such as renal failure, coronary heart disease, diabetes, hypertension and other diseases. With the improvement of living standards and changes in living habits, the incidence of hyperuricemia and gout has gradually increased, and there is a trend of younger age, which seriously threatens human health.
[0003] Natto is a popular health food. Currently, scientists have conducted in-depth research on the nutritional and health effects of natto, and it is known to have the effects of dissolving blood clots, lowering blood pressure and blood lipids, and regulating gastrointestinal function. However, there are no reports on the effects of natto and its products on lowering uric acid. Summary of the invention
[0004] In view of this, the present application provides a uric acid-lowering polypeptide and a preparation method and application thereof, aiming to provide a novel method for preparing uric acid-lowering polypeptide based on nattokinase, which has the advantages of simple process, convenient operation, and suitability for large-scale production, and the prepared uric acid-lowering polypeptide has significant uric acid-lowering effect.
[0005] The embodiment of the present application is implemented by providing a method for preparing a uric acid-lowering polypeptide, comprising: fermenting and culturing Bacillus subtilis to prepare nattokinase; enzymolyzing the nattokinase with a protease and then inactivating it to obtain a uric acid-lowering polypeptide.
[0006] In some embodiments, said protease is selected from pepsin.
[0007] In some embodiments, the enzymatic hydrolysis conditions are: using a pepsin solution with a concentration of 0.5%-1.5%, mixing according to the ratio of nattokinase activity and pepsin solution 5000-10000 IU / ml, pH value of 1.6±0.2, at 37±2°C, enzymatic hydrolysis time 1-2h; and / or,
[0008] The inactivation step is: after the enzymatic hydrolysis is completed, the temperature is raised to above 95° C. and the enzyme is inactivated for 10-15 minutes.
[0009] In some embodiments, the Bacillus subtilis is sourced from China Center for Type Culture Collection, with the accession number being CCTCC NO: M2022132.
[0010] In some embodiments, the fermentation culture uses liquid fermentation or solid fermentation.
[0011] In some embodiments, the fermentation culture adopts the liquid fermentation, and the fermentation culture of Bacillus subtilis to prepare nattokinase specifically includes: inoculating Bacillus subtilis seed liquid into the fermentation liquid at a ratio of 1% to 5% ml / 100 ml, culturing for 18 to 24 hours at 20% to 40% dissolved oxygen, 35 to 40°C, and 300 to 600rpm to obtain a fermentation stock solution; then centrifuging the fermentation stock solution, taking the supernatant, concentrating and drying it through a filter membrane to obtain liquid fermentation nattokinase powder.
[0012] In some embodiments, the supernatant is concentrated through a filter membrane to obtain a concentrated solution, and the concentrated solution is purified by composite gel filtration chromatography and cross-linked agarose ion chromatography to obtain a pure product of nattokinase with a purity greater than or equal to 99%.
[0013] In some embodiments, the fermentation culture adopts the solid fermentation, and the fermentation culture of Bacillus subtilis to prepare nattokinase specifically includes:
[0014] The soybeans and the nutrient solution are mixed in a mass volume ratio of 1:2 to 1:4, soaked at 2 to 30°C for 6 to 12 hours and then drained; wherein the nutrient solution contains: 15 to 45 g / L of glucose, 5 to 10 g / L of disodium hydrogen phosphate dodecahydrate, 0.5 to 2 g / L of sodium dihydrogen phosphate monohydrate, 0.1 to 1 g / L of magnesium sulfate, and a pH of 7.0 to 7.6; then steamed at 105 to 115°C and 0.02 MPa for 30 to 60 minutes; after steaming and cooling, seed liquid is inoculated at 1 to 10% ml / 100g, and fermented at 37 to 41°C and 75 to 85% humidity for 24 to 48 hours to obtain fermented fresh natto, and the fresh natto is dried to obtain solid fermented nattokinase powder.
[0015] The present application also provides a uric acid-lowering polypeptide obtained according to the preparation method described above.
[0016] The present application also provides an application of the above-mentioned uric acid-lowering polypeptide, and the development and application of the uric acid-lowering polypeptide in food, health food and medicine.
[0017] The present application includes at least the following beneficial effects: the preparation method of the uric acid-lowering polypeptide provided by the present application comprises: fermenting and culturing Bacillus subtilis to prepare nattokinase; enzymolyzing the nattokinase with a protease and then inactivating it to obtain the uric acid-lowering polypeptide. The novel method for preparing the uric acid-lowering polypeptide provided by the present application has the advantages of simple process, convenient operation, and suitability for large-scale production, and the prepared uric acid-lowering polypeptide has a significant uric acid-lowering effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] In order to more clearly illustrate the technical solutions in the embodiments of the present application, the drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application. For those skilled in the art, other drawings can be obtained based on these drawings without creative work.
[0019] Figure 1 This is a schematic diagram of a process for preparing a uric acid-lowering polypeptide according to an embodiment of the present application;
[0020] Figure 2 It is the standard curve of urokinase activity provided in this application. DETAILED DESCRIPTION
[0021] The technical solutions in the embodiments of the present application will be clearly and completely described below in conjunction with the drawings in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, rather than all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by those skilled in the art without making creative work belong to the scope of protection of the present application. In addition, it should be understood that the specific implementation methods described herein are only used to illustrate and explain the present application and are not used to limit the present application. In the present application, unless otherwise stated, the directional words used, such as "upper" and "lower", are specifically the directions of the drawings in the accompanying drawings. In addition, in the description of the present application, the term "including" means "including but not limited to".
[0022] Various embodiments of the present application may be presented in the form of a range; it should be understood that the description in the form of a range is only for convenience and brevity, and should not be understood as a rigid limitation on the scope of the present application; therefore, the range description should be considered to have specifically disclosed all possible sub-ranges and single numerical values within the range. For example, the range description from 1 to 6 should be considered to have specifically disclosed sub-ranges, such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as single numbers within the range, such as 1, 2, 3, 4, 5 and 6, which apply regardless of the range. In addition, whenever a numerical range is indicated herein, it is meant to include any cited number (fractional or integer) within the indicated range.
[0023] In this application, "and / or" describes the association relationship of associated objects, indicating that there may be three relationships. For example, A and / or B can mean: A exists alone, A and B exist at the same time, and B exists alone. A and B can be singular or plural.
[0024] In the present application, "at least one" means one or more, and "plurality" means two or more. "At least one", "at least one of the following" or similar expressions refer to any combination of these items, including any combination of single items or plural items. For example, "at least one of a, b, or c", or "at least one of a, b, and c" can all mean: a, b, c, ab (i.e., a and b), ac, bc, or abc, where a, b, c can be single or multiple, respectively.
[0025] The present application provides a method for preparing a uric acid-lowering polypeptide, see Figure 1 , Figure 1 This is a schematic flow chart of an embodiment of a method for preparing a uric acid-lowering polypeptide provided in the present application, comprising the following steps:
[0026] Step S11: fermenting Bacillus subtilis to prepare nattokinase;
[0027] Step S12: using a protease to enzymolyze the nattokinase, and then inactivate it to obtain a uric acid-lowering polypeptide.
[0028] The preparation method of the uric acid-lowering polypeptide provided in the present application is a biologically active protease produced by fermentation of Bacillus subtilis, i.e., Bacillus subtilis fibrinolytic enzyme, also called nattokinase, which is the main active substance in food natto, and then nattokinase is enzymolyzed to obtain a uric acid-lowering polypeptide. The preparation method of the present application has the advantages of simple process, convenient operation, and suitability for large-scale production, and the prepared uric acid-lowering polypeptide has a significant uric acid-lowering effect, and has important research and development and clinical application value. In addition, the uric acid-lowering polypeptide is a biologically active peptide substance without any toxic side effects.
[0029] It has been reported that xanthine oxidase is the rate-limiting enzyme for uric acid production, which can catalyze hypoxanthine and xanthine in sequence to finally generate uric acid. The uric acid-lowering polypeptide prepared in the present application can inhibit the activity of xanthine oxidase, that is, the uric acid-lowering polypeptide prepared in the present application can reduce the level of uric acid in serum by inhibiting the activity of xanthine oxidase, thereby achieving the effect of reducing uric acid.
[0030] In step S11:
[0031] In one embodiment, the source of Bacillus subtilis is: China Center for Type Culture Collection, with a deposit number of CCTCC NO: M2022132. The Bacillus subtilis with a deposit number of CCTCC NO: M2022132 is deposited in the National Center for Type Culture Collection, named Bacillus subtilis ZF01, classified as Bacillus subtilis, with a deposit address of Wuhan, China, and a deposit date of February 18, 2022.
[0032] Wherein, the fermentation can be liquid fermentation or solid fermentation.
[0033] In one embodiment, the fermentation is carried out using liquid fermentation. The method of fermenting Bacillus subtilis to prepare nattokinase specifically comprises: inoculating Bacillus subtilis seed liquid into the fermentation liquid at a ratio of 1% to 5% ml / 100 ml, culturing for 18 to 24 hours at 20% to 40% dissolved oxygen, 35 to 40° C., and 300 to 600 rpm to obtain a fermentation stock solution; then centrifuging the fermentation stock solution, and obtaining a liquid fermentation nattokinase powder after the supernatant is concentrated and dried through a filter membrane.
[0034] Preparation of fermentation broth: Soybean peptone 1%-3% g / 100ml, glucose 2%-5%, Na 2 HPO 4 12H 2 O1%-3%), NaH 2 PO 4 ·H 2 O 0.1%-1%, MgSO 4 7H 2 O 0.01%-0.05%, CaCl 2 0.01%-0.05%, mixed in proportion to prepare the fermentation liquid. Further, the fermentation liquid is sterilized, wherein the sterilization temperature is 110°C-120°C, and the sterilization time is 30-60min.
[0035] The preparation steps of Bacillus subtilis seed liquid are as follows: take frozen preserved seeds, rethaw, and inoculate into the liquid culture medium of the shake flask at 0.1%. In a shaking incubator, shake and culture at 180rpm and 37°C for 16-18 hours to obtain the seed liquid. The liquid culture medium contains: 15g / L glucose, 15g / L peptone, 10g / L yeast extract, 5g / L disodium hydrogen phosphate dodecahydrate, 1g / L sodium dihydrogen phosphate monohydrate, 0.2g / L magnesium sulfate, and a pH of 7.0-7.6.
[0036] Further, in one embodiment, the supernatant is concentrated through a filter membrane to obtain a concentrated solution, and the concentrated solution is purified by composite gel filtration chromatography and cross-linked agarose ion chromatography to obtain a pure product of nattokinase, with a purity greater than or equal to 99%. This pure product of nattokinase is used for enzymolysis in subsequent step S12.
[0037] In another embodiment, the fermentation uses solid fermentation. The fermentation culture of Bacillus subtilis to prepare nattokinase specifically includes: washing and removing impurities from soybeans, mixing soybeans and nutrient solution according to a mass volume ratio of 1:2 to 1:4, soaking at 2 to 30 ° C for 6 to 12 hours and then draining; wherein the nutrient solution contains: 15 to 45 g / L of glucose, 5 to 10 g / L of disodium hydrogen phosphate dodecahydrate, 0.5 to 2 g / L of sodium dihydrogen phosphate monohydrate, 0.1 to 1 g / L of magnesium sulfate, and a pH of 7.0 to 7.6. Then steam at 105 ° C to 115 ° C and 0.02 MPa for 30 to 60 minutes. After steaming and cooling, the seed liquid is inoculated at 1 to 10% ml / 100g of the weight of the raw material, and fermented in a fermentation equipment for 24 to 48 hours to obtain fermented fresh natto, wherein the temperature in the fermentation equipment is controlled at 37 to 41 ° C and the humidity is 75 to 85%; the fresh natto is dried to obtain solid fermentation nattokinase powder.
[0038] It is understandable that the mixing in this step can be carried out by common mixing methods such as stirring and ultrasound, which are not limited here. In addition to centrifugal separation to obtain the supernatant, common solid-liquid separation methods such as filtration and sieving can also be used, which are not limited here.
[0039] In step S12:
[0040] The nattokinase is enzymolyzed using a protease, specifically using a protease to enzymolyze one or more of the pure nattokinase, liquid fermentation nattokinase and solid fermentation nattokinase in step S11, that is, the pure nattokinase, liquid fermentation nattokinase and solid fermentation nattokinase prepared in step S11 can all be used as enzymolysis substrates. The uric acid-lowering polypeptides obtained by enzymolysis of different enzymolysis substrates including pure nattokinase, liquid fermentation nattokinase and solid fermentation nattokinase all have good efficacy.
[0041] In one embodiment, the protease is selected from one or more of pepsin, trypsin and papain. Preferably, the protease is selected from pepsin.
[0042] In a specific embodiment, the reaction conditions of enzymolysis are: concentration 0.5%-1.5% g / 100ml pepsin solution, pH value 1.6±0.2, nattokinase activity and pepsin solution ratio 5000-10000 IU / ml, enzymolysis at 37±2°C, enzymolysis time 1-2h; after the enzymolysis is completed, the temperature is raised to above 95°C and the enzyme is inactivated for 10-15min.
[0043] The present application provides a uric acid-lowering polypeptide, which is prepared by the preparation method of the uric acid-lowering polypeptide provided in the present application. The present application also provides the development and application of the uric acid-lowering polypeptide in food, health food and medicine, so as to be applied to the treatment and health care of hyperuricemia.
[0044] The technical scheme and technical effects of the present application are described in detail below through specific embodiments, comparative examples and experimental examples. The following embodiments are only some embodiments of the present application and do not specifically limit the present application. It can be understood that the reagents used in each embodiment, comparative example and experimental example are all commercially available reagents unless otherwise specified.
[0045] Example 1
[0046] This embodiment provides a method for preparing a uric acid-lowering polypeptide, comprising the following steps:
[0047] 1. Prepare fermentation liquid: 2% g / 100 ml of soy peptone, 3% glucose, Na 2 HPO 4 12H 2 O 2%, NaH 2 PO 4 ·H2O 0.5%, MgSO 4 7H 2 O 0.02%, CaCl 2 0.02%, mixed according to the proportion to prepare the fermentation liquid;
[0048] 2. Fermentation
[0049] Take frozen seeds, thaw them, and inoculate 0.1% of the liquid culture medium in a shake flask. Shake and culture them in a shaking incubator at 180rpm and 37°C for 16-18 hours to obtain seed liquid. The liquid culture medium contains: 15g / L glucose, 15g / L peptone, 10g / L yeast extract, 5g / L disodium hydrogen phosphate dodecahydrate, 1g / L sodium dihydrogen phosphate monohydrate, 0.2g / L magnesium sulfate, pH 7.0-7.6.
[0050] The Bacillus subtilis seed solution is inoculated into the fermentation solution at a ratio of 3% ml / 100 ml, and the fermentation solution is cultured for 20 hours at 30% dissolved oxygen, 35-40° C., and 300-600 rpm;
[0051] 3. Separation: Centrifuge the fermentation liquid to obtain the supernatant, concentrate and dry it through a filter membrane to obtain liquid fermented nattokinase powder.
[0052] 4. Determination of Nattokinase Activity:
[0053] (1) Reagent preparation:
[0054] Solution A: Weigh 121.1g of Tris and add water to dissolve it. Use about 42ml of concentrated hydrochloric acid to adjust the pH to 8.0. Finally, dilute to 1L as the mother solution. Take 10ml of the mother solution and dilute to 500ml with water to obtain Solution A.
[0055] Solution B: Weigh 9g of NaCl, add water to dissolve, and make up to 1L.
[0056] 50mg / ml fibrinogen solution: weigh 1g of fibrinogen powder (content 50-70%) and dissolve it in 20ml of solution A to fully dissolve it.
[0057] 100U / ml thrombin solution: Dissolve 1000U thrombin in 10ml of solution A and allow it to fully dissolve.
[0058] Urokinase solution standard: First, take 2 ml of sterile saline (0.9% W / V) to dissolve the urokinase standard (1240 IU / tube) to make a 620 IU / ml solution. Then take 1 ml from the above solution into another small tube containing 1 ml of saline to make a 310 IU / ml solution, and dilute it into 155 IU / ml, 77.5 IU / ml, 38.75 IU / ml, and 19.375 IU / ml standard urokinase solutions in sequence for use.
[0059] (2) Experimental methods:
[0060] Preparation of fibrin plate: weigh 0.15g agar (0.75%) and 0.1755g NaCl (0.15M), add to a 50ml small conical flask; measure 20ml of solution A to dissolve the agar; stopper the conical flask and place it in a microwave oven to heat and dissolve; when the conical flask cools to 50℃, add 1ml of 50mg / ml fibrinogen solution and 100μl of 100U / ml thrombin to the flask, mix well and quickly pour into a sterilized plate; leave at room temperature for 30min to form a fibrin clot.
[0061] Preparation of the sample solution: Take an appropriate amount of the sample to be tested, add Solution B to dissolve it, and dilute it to a concentration within the range of the standard curve. If the sample is solid, centrifuge it after dissolution and take the supernatant for testing.
[0062] Draw a urokinase standard curve: Use a hole puncher to punch 7 holes on a fibrin plate and mark them; take 10 μl of standard urokinase solution of each concentration into the corresponding hole, place it for 10 minutes, and then transfer it to a 37°C constant temperature incubator for reaction. After 18 hours, take out and measure the two vertical diameters of each dissolution circle; set three parallel groups for the above operation, and take the average value after measurement; then use the common logarithm of the product of the vertical diameters (S) as the horizontal axis and the common logarithm of the standard urokinase concentration as the vertical axis to make a urokinase enzyme activity standard curve, see Figure 2 .
[0063] Determination of thrombolytic activity of the sample to be tested: Take 10ul of the sample to be tested and load it on the same plate according to the above operation, react in a constant temperature incubator at 37℃, measure the two vertical diameters of the dissolution circle after 18 hours, and calculate the enzyme activity of the sample according to the standard curve method and dilution concentration.
[0064] The measurement results are shown in Table 1.
[0065] 5. Enzymolysis: Add pepsin solution with a final concentration of 1% to the natto powder in step 3, with a pH value of 1.6 and a ratio of nattokinase activity to pepsin solution of 6000 IU / ml, and perform enzymolysis at 37°C for 1.5 h (1-2 h); after the enzymolysis is completed, heat the mixture to above 95°C and inactivate the enzyme for 10 min (10-15).
[0066] 6. Drying: The enzymatic hydrolysate is dried to obtain uric acid-lowering polypeptides.
[0067] Example 2
[0068] This embodiment provides a method for preparing a uric acid-lowering polypeptide, which is different from that of Example 1 in that the concentrate after concentration by the filter membrane in step 3 is further purified by composite gel filtration chromatography and cross-linked agarose ion chromatography, and dried to obtain a pure product of nattokinase (with a purity exceeding 99%). The remaining steps are the same.
[0069] Example 3
[0070] This embodiment provides a method for preparing a uric acid-lowering polypeptide, comprising the following steps:
[0071] The soybeans are washed and impurities are removed, and the soybeans and nutrient solution are mixed in a mass volume ratio of 1:3, soaked at 8°C for 12 hours, and then drained; wherein the nutrient solution contains: 30g / L glucose, 8g / L disodium hydrogen phosphate dodecahydrate, 0.5g / L sodium dihydrogen phosphate monohydrate, 0.5g / L magnesium sulfate, and pH is 7.0. Then steamed at 105°C and 0.02MPa for 40 minutes. After steaming and cooling, seed liquid is inoculated at 5% ml / 100g of the weight of the raw material, and fermented in a fermentation equipment for 36 hours to obtain fermented fresh natto, wherein the temperature in the fermentation equipment is controlled at 37-41°C and the humidity is 75-85%; the fresh natto is dried to obtain solid fermented nattokinase powder.
[0072] The subsequent steps are the same as steps 4-6 of Example 1.
[0073] Example 4
[0074] Xanthine oxidase inhibition rate test:
[0075] The dual enzyme method was used to determine the inhibition rate of the sample on xanthine oxidase. In the dual enzyme coupling method, xanthine is decomposed by xanthine oxidase to produce H2O2. In the process of horseradish peroxidase catalyzing H2O2, 4-aminoantipyrine and phenol form a red compound, which will produce an absorbance value at 508nm, and the xanthine oxidase inhibition activity can be calculated.
[0076] Specific method: add 200 μL of sample solution and 50 μL of 0.5 U / mL xanthine oxidase solution to a 10 mL colorimetric tube, vortex and mix, and keep warm at 37°C for 10 min. Then add 400 μL of 2.0 mmol / L xanthine solution and 3 mL of colorimetric solution to start the reaction; keep warm at 37°C for 20 min; boil for 5 min, cool to room temperature; measure the absorbance at 508 nm. The blank group A0 is the group without xanthine added; the positive blank group Ac is the group without sample added; the zero adjustment group is the group without xanthine oxidase added; the measurement group is As; the calculation formula is: XOD inhibition rate of the sample (%) = (Ac-(As-A0)) / Ac*100.
[0077] Example 5
[0078] Comparison of different enzymatic hydrolysis / degradation methods:
[0079] The difference compared with Examples 1, 2 and 3 is that trypsin and papain treatments are added, and strong acid degradation treatment is added. Three methods are used: 1% trypsin solution with a pH value of 8.0, 1% papain solution with a pH value of 6.8 and dilute hydrochloric acid with a pH value of 1.6, and enzymolysis / degradation is performed at 37°C for 1.5 hours. Others are the same as in Example 1.
[0080] The xanthine oxidase inhibition rates of uric acid-lowering polypeptides prepared by different enzymatic hydrolysis methods were detected, and a control without enzymatic hydrolysis treatment was set up.
[0081] Table 1 Activity results of different enzymatic hydrolysis raw materials
[0082] Serial number Grouping active 1 Liquid fermented nattokinase 10w IU / g 2 Pure Nattokinase 1.5w IU / ml 3 Solid fermentation nattokinase 7w IU / g
[0083] Table 2 Xanthine oxidase inhibition rate of uric acid-lowering polypeptides by different enzymatic hydrolysis methods (%)
[0084]
[0085] The results are shown in Table 2. The xanthine oxidase inhibition rates of the uric acid-lowering polypeptides obtained by enzymatic hydrolysis with 1% pepsin solution were the highest, at 86.47%, 69.92% and 75.38%, respectively.
[0086] Compared with the blank enzyme solution and the nattokinase without enzyme treatment, the xanthine oxidase inhibition rates of liquid fermented natto, pure nattokinase and solid fermented natto after pepsin treatment (86.47%, 69.92% and 75.38%) were significantly higher than those of the untreated group (35.09%, 30.48% and 31.26%), and the control blank enzyme solution was only 7.15%.
[0087] Compared with trypsin, papain and strong acid treatment, the xanthine oxidase inhibition rates of liquid fermented natto, pure nattokinase and solid fermented natto after pepsin treatment (86.47%, 69.92% and 75.38%) were higher than those of the trypsin treatment group (10.27%, 9.57% and 12.68%), papain treatment group (15.08%, 10.55% and 11.91%) and strong acid treatment group (23.58, 19.26 and 21.37).
[0088] Pepsin has strong specificity, and its action site is mainly the peptide bond formed by aromatic amino acids or leucine. There are more than 30 such sites in the nattokinase sequence, so nattokinase is very sensitive to pepsin cleavage and is easily destroyed by pepsin. Because nattokinase is an alkaline protease, its own protein structure cannot tolerate a highly acidic environment, and it is difficult to maintain its own spatial structure in an acidic environment. The destruction of the spatial structure leads to the exposure of the pepsin target site inside the protein, and ultimately nattokinase is destroyed by pepsin into small peptides.
[0089] Compared with the three groups of pepsin treatment, the liquid fermented natto group (86.47%) and the solid fermented natto group (75.38%) were higher than the pure nattokinase group (69.92%). The fermented nattokinase powder contains small molecule peptides, various amino acids, multiple vitamins and other bioactive factors, as well as a variety of antibacterial and antioxidant substances produced by Bacillus subtilis, which can produce a certain coordination and promotion effect.
[0090] Application Examples
[0091] The application example of the present invention provides a uric acid-lowering function test of a uric acid-lowering polypeptide, and the specific operation is as follows:
[0092] Establishment of hyperuricemia mouse model: Adult Kunming mice were given potassium oxonate 400 mg / kg combined with hypoxanthine 500 mg / kg daily, with potassium oxonate injected intraperitoneally and hypoxanthine administered by gavage for 14 consecutive days. After that, venous serum of mice was collected and the serum uric acid level of mice was detected by ELISA kit. The level of uric acid in the model group was 195.84 μmol / L, which was significantly higher than that in the normal group 86.14 μmol / L, indicating that the model was successful.
[0093] Animal grouping and administration method: 72 adult Kunming mice were selected and randomly divided into 2 groups, 12 in the normal group, and the remaining 60 mice were randomly divided into 5 groups after the model was successfully established. The grouping is shown in Table 3, including the model group, the positive group, and the uric acid-lowering polypeptides obtained in Examples 1, 2, and 3. Then, the test samples of each experimental group were orally administered, and the normal group and the model group were gavaged with an equal volume of physiological saline; the positive group was administered with a dose of 50 mg / Kg of allopurinol, and the daily dose of the test samples of each experimental group was 100 mg / Kg, once a day, for 28 consecutive days, and then the serum uric acid level of each group was measured.
[0094] Results: The results of serum uric acid determination in each group of animals are shown in Table 4.
[0095] Table 3 The results of determination of serum uric acid in animals before and after modeling
[0096] Grouping Uric acid level (μmol / L) Normal group: 12 86.14±5.24 The remaining model group 60 195.84±8.18*
[0097] Table 4 Results of determination of serum uric acid in each group of animals (n=12)
[0098] Grouping Uric acid level (μmol / L) Normal group 86.14±5.24 Model Group 189.52±9.05* Positive Control <![CDATA[87.34±6.51 # ]]> Example 1 Group <![CDATA[88.27±4.15 # ]]> Example 2 Group <![CDATA[105.24±4.68 # <!-- 7 -->]]> Example 3 Group <![CDATA[93.57±5.91 # ]]>
[0099] Note: Compared with the normal group, *p<0.05. Compared with the model group, #p<0.05.
[0100] As can be seen from Table 3, the modeling was successful.
[0101] As shown in Table 4, compared with the model group, the serum uric acid of each group of animals in the three embodiment groups decreased after the test. The uric acid-lowering polypeptides prepared by liquid fermentation nattokinase in embodiment 1 group and solid fermentation nattokinase in embodiment 3 group were more effective, and the serum uric acid level dropped to a level close to that of the normal group, which was closest to the positive control group. The fermented nattokinase powder contains biologically active factors such as small molecule polypeptides, various amino acids, and multiple vitamins, and has strong antioxidant and free radical scavenging capabilities; it also contains a variety of antibacterial and antioxidant substances produced by Bacillus subtilis, including bacteriocins, superoxides, polypeptides, and antibacterial proteins. These active factors, together with the uric acid-lowering polypeptides, have a synergistic effect in promoting the lowering of uric acid.
[0102] The above is a detailed introduction to the uric acid-lowering polypeptides and their preparation methods and applications provided in the examples of the present application. Specific examples are used herein to illustrate the principles and implementation methods of the present application. The description of the above embodiments is only used to help understand the methods and core ideas of the present application. At the same time, for those skilled in the art, according to the ideas of the present application, there will be changes in the specific implementation methods and application scopes. In summary, the content of this specification should not be understood as a limitation on the present application.
Claims
1. A method for preparing a uric acid-lowering polypeptide, characterized in that: include: Fermenting and culturing Bacillus subtilis to prepare nattokinase; The nattokinase is enzymatically hydrolyzed by protease and then inactivated to obtain a uric acid-lowering polypeptide.
2. The preparation method according to claim 1, characterized in that: The protease is selected from pepsin.
3. The preparation method according to claim 2, characterized in that: The conditions for the enzymolysis are: using a pepsin solution with a concentration of 0.5%-1.5%, mixing according to the ratio of nattokinase activity and pepsin solution 5000-10000 IU / ml, pH value of 1.6±0.2, at 37±2° C., enzymolysis time of 1-2 h; and / or, The inactivation step is: after the enzymatic hydrolysis is completed, the temperature is raised to above 95° C. and the enzyme is inactivated for 10-15 minutes.
4. The preparation method according to claim 2, characterized in that: The source of the Bacillus subtilis is: China Center for Type Culture Collection, with a collection number of CCTCC NO: M2022132.
5. The preparation method according to any one of claims 1 to 4, characterized in that: The fermentation culture adopts liquid fermentation or solid fermentation.
6. The preparation method according to claim 5, characterized in that: The fermentation culture adopts the liquid fermentation, and the fermentation culture of Bacillus subtilis to prepare nattokinase specifically includes: inoculating Bacillus subtilis seed liquid into the fermentation liquid at a ratio of 1% to 5% ml / 100 ml, culturing for 18 to 24 hours at 20% to 40% dissolved oxygen, 35 to 40° C., and 300 to 600 rpm to obtain a fermentation stock solution; then centrifuging the fermentation stock solution, taking the supernatant, concentrating and drying it through a filter membrane, and obtaining liquid fermentation nattokinase powder.
7. The preparation method according to claim 6, characterized in that: The supernatant is concentrated through a filter membrane to obtain a concentrated solution, and the concentrated solution is purified through composite gel filtration chromatography and cross-linked agarose ion chromatography to obtain a pure product of nattokinase with a purity greater than or equal to 99%.
8. The preparation method according to claim 5, characterized in that: The fermentation culture adopts the solid fermentation, and the fermentation culture of Bacillus subtilis to prepare nattokinase specifically includes: The soybeans and the nutrient solution are mixed in a mass volume ratio of 1:2 to 1:4, soaked at 2 to 30°C for 6 to 12 hours and then drained; wherein the nutrient solution contains: 15 to 45 g / L of glucose, 5 to 10 g / L of disodium hydrogen phosphate dodecahydrate, 0.5 to 2 g / L of sodium dihydrogen phosphate monohydrate, 0.1 to 1 g / L of magnesium sulfate, and a pH of 7.0 to 7.6; then steamed at 105 to 115°C and 0.02 MPa for 30 to 60 minutes; after steaming and cooling, inoculated with Bacillus subtilis seed liquid at 1 to 10% ml / 100g, fermented at 37 to 41°C and 75 to 85% humidity for 24 to 48 hours to obtain fermented fresh natto; the fresh natto is dried to obtain solid fermented nattokinase powder.
9. The uric acid-lowering polypeptide obtained according to the preparation method according to any one of claims 1 to 8.
10. The use of the uric acid-lowering polypeptide according to claim 9, characterized in that: Development and application of uric acid-lowering peptides in food, health food and medicine.
Citation Information
Cited By
Hyperuricemia modeling method based on combination of yeast feed and medicines
CN121220423A
